Core Viewpoint - The company, Stone Pharmaceutical Group, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for its drug, Daratumumab injection [1] Group 1: Product Development - The product is a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosyl cyclase (CD38) [1] - It is a biosimilar to the original drug, Darzalex, and is classified under Category 3.3 for therapeutic biological products [1] - The drug is intended for the treatment of adult patients with multiple myeloma [1] Group 2: Research and Compliance - The development of the product adheres to the relevant research guidelines for biosimilars [1] - Pharmaceutical and non-clinical research results indicate that the product is highly similar to the reference drug in terms of quality, safety, and efficacy, supporting further clinical research [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 自願公告 達雷妥尤單抗注射液 在中國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的達雷妥尤單抗注射液（「該產品」）已獲中華人民共和國國家藥品監督管理 局批准，可在中國開展臨床試驗。 該 產 品 是 一 種 靶 向 ADP - 核 糖 基 環 化 酶 (CD38) 的 重 組 全 人 源 Ig G1 單 克 隆 抗 體 ， 為 原 研 藥 兆 珂®的生物類似藥，按照治療用生物製品3.3類申報，適用於治療多發性骨髓瘤成年患者。 該產品研發遵循生物類似藥相關研究指導原則，藥學及非臨床研究結果顯示，該產品與原 研參照藥在質量、安全性和有效性方面高度相似，支持開展後續臨床研究。 ...

Core Viewpoint - The Hong Kong stock market experienced a net inflow of 611 million HKD from northbound trading on December 23, with significant buying in Alibaba, Meituan, and Zijin Mining, while China Mobile, Tencent, and SMIC saw the most selling [1][6]. Group 1: Northbound Trading Activity - Northbound trading recorded a net buy of 611 million HKD, with Shanghai Stock Connect showing a net sell of 582 million HKD and Shenzhen Stock Connect showing a net buy of 1.193 billion HKD [1]. - The most bought stocks included Alibaba-W (09988), Meituan-W (03690), and Zijin Mining (02899) [1]. - The most sold stocks included China Mobile (00941), Tencent (00700), and SMIC (00981) [1]. Group 2: Stock-Specific Details - Alibaba-W (09988) had a net buy of 13.67 billion HKD, driven by the launch of the AI DingTalk operating system [2][6]. - Meituan-W (03690) received a net buy of 2.23 billion HKD [8]. - Zijin Mining (02899) saw a net buy of 1.11 billion HKD, with an upgraded production forecast for its copper project [6]. - China Mobile (00941) faced a net sell of 14.82 billion HKD [2]. - Tencent (00700) experienced a net sell of 7.78 billion HKD [2]. - SMIC (00981) had a net sell of 6.29 billion HKD, influenced by U.S. export regulations on AI chips [7].

Core Viewpoint - The increasing consumer willingness to invest in health-related products, such as probiotics, is driving interest in companies like 科郦有限公司, which is preparing for an IPO in Hong Kong [1] Company Overview - 科郦 is the exclusive distributor of妈咪爱 and 易坦静 in China's outpatient market and is recognized as the largest pediatric pharmaceutical marketing, promotion, and sales service provider in China [1][5] - The company has maintained a long-term partnership with 韩美集团 since 2007, relying heavily on them for product supply [5][13] - As of 2024, the company expects to generate approximately $282 million (about 1.98 billion RMB) in revenue with a gross margin exceeding 53% [1] Revenue Breakdown - During the reporting period from 2022 to the first half of 2025, over 86% of the company's revenue came from pharmaceutical marketing, promotion, and sales, while maternal and nutritional supplements accounted for about 7% [5][6] - The revenue from pharmaceutical marketing, promotion, and sales for 2022, 2023, 2024, and the first half of 2025 was approximately $322 million, $350 million, $282 million, and $143 million, respectively [15][16] Market Position - The company is positioned as the eighth largest pharmaceutical marketing and sales service provider in China, holding a market share of 1.8%, and is the largest in pediatric pharmaceutical marketing with a 15.9% market share [19] - The Chinese probiotics supplement market is projected to grow from 24.6 billion RMB in 2024 to 40 billion RMB by 2029, with a compound annual growth rate of 10.2% [17] Financial Performance - The company's gross profit margins have shown an upward trend, increasing from 43.6% in 2022 to 56% in 2025, driven by reduced procurement costs and improved pricing negotiations with suppliers [17] - However, the company experienced a revenue decline in 2024 due to a post-pandemic market slowdown and strategic refocusing on core business areas [15][17] Competitive Landscape - The pharmaceutical distribution market in China is highly competitive, with major players including 华润医药, 上海医药, and 复星医药 [19] - The government has been expanding centralized procurement plans, which has led to price reductions and intensified competition, potentially impacting the company's pricing strategies and profit margins [19] Company Structure and Leadership - 科郦 was established in Hong Kong in 2009 and has a workforce of 1,014 employees, with a significant portion in sales and marketing [21][23] - The company is led by 林钟润, who holds a 76.2% stake, and 韩星俊, the CEO, who has extensive experience in the pharmaceutical and healthcare sectors [21][24] IPO Plans - The funds raised from the IPO will be used to expand the sales network and product portfolio, enhance production capacity, and improve brand value for its two main brands,妈咪爱 and COREE [24]

Market Overview - The Hong Kong stock market opened slightly higher but weakened throughout the day, with all three major indices turning negative by the close. The Hang Seng Index fell by 0.11% to 25,774.14 points, with a total turnover of HKD 157.13 billion [1] - The Hang Seng China Enterprises Index decreased by 0.29% to 8,913.83 points, while the Hang Seng Tech Index dropped by 0.69% to 5,488.89 points [1] Blue Chip Performance - CSPC Pharmaceutical Group (01093) led the blue-chip stocks, rising by 7.64% to HKD 8.88, contributing 8.08 points to the Hang Seng Index. The stock had a turnover of HKD 2.76 billion [2] - Other notable blue-chip movements included Tingyi (00322) up by 2.07% to HKD 12.35, and China Resources Power (00836) up by 1.25% to HKD 17.8. Tencent Holdings (00700) and China Unicom (00762) both fell by 2.03%, dragging the index down by 42.3 points and 1.68 points respectively [2] Sector Highlights - Large tech stocks showed mixed performance, with Alibaba rising by 0.55% while Tencent fell by 2.03% [3] - Gold stocks initially surged but later retreated, with Shandong Gold (01787) closing up by 4.64% at HKD 37.86. The international gold price reached a historic high, with COMEX gold futures surpassing USD 4,500 per ounce [4][3] - Lithium battery stocks were active, with Ganfeng Lithium (01772) rising by 4.08% to HKD 56.15, and CATL's lithium production news causing market fluctuations [4][5] Upcoming Market Events - A wave of stock unlocks is expected in the Hong Kong market, with over ten companies, including Sanhua Intelligent Control and Yujing, having significant shareholder unlocks from December 16 to 31 [6] - Yujing's shares will be unlocked for 36 shareholders, totaling approximately 193 million shares, while Sanhua Intelligent Control will see 17 shareholders unlock around 196 million shares [6] Notable Stock Movements - New stocks had varied performances on their debut, with Nobikang (02635) soaring by 363.75% to HKD 371, while Hantang Aitai (03378) plummeted by 46.25% to HKD 17.2 [7] - Dongfang Electric (01072) showed strong performance, rising by 8.17% to HKD 25.94, benefiting from its position in the high-end energy equipment sector [8] - Cathay Pacific (00293) reported expected net profits exceeding HKD 9.88 billion (USD 1.3 billion) for 2025, marking a potential for consecutive annual profit growth for the first time in a decade [9] - Tmall's stock faced pressure, declining by 4.49% to HKD 2.98, with a reported year-on-year decline in retail and wholesale sales [10]

Core Viewpoint - The article discusses the recent performance and market outlook of CSPC Pharmaceutical Group (01093), highlighting the divergence in institutional views regarding the company's short-term operational challenges and long-term business development (BD) potential [4][5]. Technical Analysis - CSPC's stock price recently recovered above the 10-day moving average (approximately 7.75 HKD) and stabilized above the 30-day moving average (approximately 7.74 HKD), indicating a strengthening short-term momentum [1]. - The Relative Strength Index (RSI) has reached 61, suggesting overbought pressure, which may lead to a technical correction to digest profit-taking and build new momentum [1]. - The stock is facing a key resistance level at 8.49 HKD; a successful breakout could target 9.03 HKD, while support is at 7.79 HKD, with a critical level at 7.47 HKD [1]. Market Perspectives - There is a significant divergence in market opinions regarding CSPC's future, with optimistic views focusing on the company's sustainable growth drivers through BD transactions [4]. - UBS raised its target price to 10 HKD, citing untapped potential in BD transactions and effective sales expense control [4]. - Conversely, Daiwa downgraded CSPC from "Hold" to "Sell," arguing that the stock price reflects optimistic expectations for BD transactions while the core pharmaceutical sales face growth pressures [5]. Derivative Instruments - In light of the stock's critical resistance levels and market divergence, warrants and bull/bear certificates offer investors flexible tools to respond to short-term volatility without large direct stock purchases [6]. - Recent performance of derivative products shows that when CSPC's stock rose by 3.00% over two trading days, linked warrants experienced price increases of 19%, 14%, and 12% respectively, demonstrating the leverage effect of these instruments [6]. Product Selection Guidance - Investors optimistic about breaking the 8.49 HKD resistance may consider higher strike price warrants, such as those from Morgan Stanley and Société Générale, which offer relatively high leverage [9]. - For those anticipating a potential pullback, Société Générale's bear certificate with a redemption price set at 9.5 HKD provides a higher leverage option for bearish strategies [9].

Market Performance - Huazhong Biopharmaceutical (02396) saw a significant drop of nearly 30% on its debut and continued to decline by over 17% today. The company, established in 2012, focuses on the discovery, development, and commercialization of wound healing therapies, but has not generated any revenue from product sales yet [1] - Zai Lab (02617) fell by over 16% following the unlocking of cornerstone lock-up shares on December 23 [1] - China Rare Earth Holdings (03788) increased by over 7% after announcing plans to spin off its subsidiary "Rare Earth Gold" for independent listing on the Hong Kong Stock Exchange [1] - Goldwind Technology (02208) rose nearly 1% as the world's largest integrated green hydrogen and ammonia project, built by China Energy Engineering, officially commenced production [1] - Guizhou Zhenjiu (06979) saw an increase of over 4% after announcing a phased halt to large-scale recruitment in certain regions, which has shown significant progress during the industry's adjustment period [1] Company Developments - Taobo (06110) experienced a decline of over 7% as it reported a high single-digit year-on-year drop in total sales for its retail and wholesale business for the third quarter of the 2025/26 fiscal year [2] - CSPC Pharmaceutical Group (01093) rose nearly 6% after its chairman increased his stake by acquiring 13.454 million shares at approximately HKD 8.1957 per share, totaling around HKD 110 million [2] - Shandong Gold (01787) increased by nearly 6% as spot gold prices reached a historical high of USD 4,400 per ounce, with predictions from JPMorgan estimating an average gold price of USD 5,055 per ounce by Q4 2026 [2] Industry Trends - The dairy sector saw active trading, with companies like Modern Dairy (01117), Original Ecology Dairy (01431), Mengniu Dairy (02319), and China Feihe (06186) all experiencing gains. This follows the Ministry of Commerce's announcement of temporary anti-subsidy measures on dairy products imported from the EU starting December 23, 2025 [3] - CIMC Enric (03899) rose by over 7% after signing a memorandum of cooperation with the Yangpu Economic Development Zone Management Committee at a recent offshore wind power industry chain conference [4] US Market Highlights - The US solar energy sector saw strong performance, with companies like Sunrun (RUN.US) and Canadian Solar (CSIQ.US) rising by 10.84% and 10.78% respectively, following a Goldman Sachs report indicating a structural investment window in the solar sector [5] - Cytokinetics (CYTK.US) increased by 4.59% after receiving priority review approval for its innovative drug, which treats obstructive hypertrophic cardiomyopathy in adults [5] - Tesla (TSLA.US) rose by 1.56% as a prominent analyst expressed optimism about the company's expansion of its autonomous taxi service by 2026 [6] - Quantum computing stocks surged, with D-Wave Quantum (QBTS.US) rising by 20.02% and IonQ Inc (IONQ.US) by 11.1% [6] - Cryptocurrency stocks continued to rise, with Hut 8 (HUT.US) increasing by 14.21% as Bitcoin and Ethereum prices surged [7]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant trading activity and price increases among leading innovative drug companies, indicating a positive shift in market sentiment towards this sector [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) reached a peak increase of 1.53% and traded over 140 million yuan during the session [1]. - Leading companies in the innovative drug sector, such as CSPC Pharmaceutical Group, recorded gains exceeding 5%, while others like 3SBio and Hengrui Medicine saw increases of over 2% [1]. Group 2: Investment Insights - Analysts from Zhongtai Securities noted that the current innovative drug market differs from the 2019-2021 period, as the sector is transitioning from narrative to actual performance, with trading volumes hitting new highs [1]. - Long-term support from domestic policies for innovative drugs is evident, with the introduction of commercial insurance directories enhancing payment capabilities [1][3]. - Changjiang Securities emphasized the emergence of a new policy support cycle for the pharmaceutical industry, particularly for innovative drugs, suggesting a focus on high-quality assets with strong overseas potential [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) is designed to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three key advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms, and employs risk control measures for less liquid stocks [3][4]. - The top ten holdings in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]. Group 4: Alternative Investment Options - For investors seeking to mitigate volatility while still focusing on innovative drugs, the only ETF in the market (562050) offers a mix of innovative and traditional Chinese medicine stocks, providing a balanced approach [4].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant trading activity and price increases among leading innovative drug companies, indicating a shift in the market dynamics for innovative pharmaceuticals in China [1][3]. Group 1: Market Performance - On December 23, the Hong Kong Stock Connect innovative drug ETF (520880) reached a peak increase of 1.53% and recorded over 1.4 billion yuan in trading volume [1]. - Leading companies in the innovative drug sector, such as CSPC Pharmaceutical Group, saw stock price increases exceeding 5%, while others like 3SBio and Hengrui Medicine rose over 2% [1]. Group 2: Investment Insights - Analysts from Zhongtai Securities noted that the current innovative drug market differs from the 2019-2021 period, as it has transitioned from narrative to actual performance, with trading volumes hitting new highs, reflecting a leap in China's innovative capabilities [1]. - Changjiang Securities emphasized that the innovative drug sector is entering a new cycle of policy support, suggesting a focus on high-quality innovative drug assets with strong overseas potential [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms (over 72% in the top ten), and employs measures to control risks associated with less liquid stocks [3][4]. - The ETF's current market price is close to its initial listing price, presenting a potential value opportunity for investors [3]. Group 4: Composition and Strategy - The top ten holdings of the Hong Kong Stock Connect innovative drug ETF account for 72.57% of the total weight, showcasing significant dominance by leading companies in the sector [4]. - For investors seeking to mitigate volatility while still focusing on innovative drugs, alternative ETFs that include a mix of traditional Chinese medicine and innovative drugs are available, providing a balanced investment approach [4].

12月23日，石药集团(1093.HK)持续上涨行情，目前涨5.5%报8.7港元，近4日累计升幅近20%，总市值 重回千亿港元大关。 消息上，根据香港联交所最新披露的文件，蔡东晨于12月22日以每股均价8.1957港元增持石药集团345.4 万股普通股股份，价值约1.1亿港元。增持后，蔡东晨最新持股数目为29.1亿股股份，好仓比例由 25.14%升至25.26%。 本文源自：格隆汇 ...